SPP1 and metastatic neoplasm: The levels of plasma osteopontin in the cohort with metastatic disease was significantly increased compared to controls (p < 0.0001), and additionally, fl-OPN levels were further increased in patients with three or more sites of metastatic involvement compared to one or two metastatic sites.